The company is developing an epilepsy test based on inflammatory proteins in patient blood that is intended for ruling out patients with seizure-like symptoms.
NEW YORK (GenomeWeb News) – MRIGlobal and Evogen today announced a five-year agreement to develop molecular diagnostic products targeting the in vitro and clinical molecular diagnostic markets.
Evogen, a Lenexa, Kansas-based developer of molecular detection and diagnostic technologies, said this week that it has non-exclusively licensed its PCR probe technology to Focus Diagnostics, a Quest Diagnostics subsidiary.
NEW YORK (GenomeWeb News) – Evogen has granted Focus Diagnostics a license to incorporate Evogen's HyBeacons PCR probe technology into Focus' molecular diagnostic products and services, the firms announced today.
The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.
